Phylogica gets Australian Phylomer patent
Phylogica (ASX:PYC) has secured a key Australian patent covering its portfolio of Phylomer peptide libraries.
The patent covers the company’s Phylomer libraries as a composition of matter, regardless of how they are constructed or screened. It allows the peptides to comprise genomes including bacteria, protozoa, algae and even vertebrates.
Phylogica holds similar patents in other regions, including the European Union.
Phylogica CEO Paul Watt said the patents “confirm Phlyogica’s dominant IP position over the Phylomer peptide class [and] protect recent upgrades to the Phylomer platform, which have enhanced the overall complexity of the phage libraries”.
“Our IP estate blocks potential competitors and controls access to this rich resource of drug-like peptides by any current or future means, since we have protected the Phylomer libraries themselves, in addition to multiple methods of constructing and screening them.”
The company’s Phylomer libraries include over 170 billion compounds. Phylogica uses the libraries to provide drug discovery services to the pharmaceutical industry.
Major partners include Pfizer, which is collaborating with the company on a drug discovery project, as well as Roche, MedImmune and Janssen.
Phylogica shares were trading 14.29% higher at $0.024 as of around 2 pm on Friday.
Stevia leaf extract has potential as an anticancer treatment
When fermented with bacteria isolated from banana leaves, stevia extract kills off pancreatic...
Even non-antibiotics can disrupt the microbiome
Many non-antibiotics inhibit useful gut bacteria, giving rise to an imbalance in the microbiome,...
How brain stem cells move between resting and active states
Understanding this process is crucial, because it underpins how the brain repairs itself and...
